iOmx Therapeutics raises EUR 65 million in Series B round
The new funds will be used to advance iOmx´ lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology
08-Oct-2021 -
iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the closing of a Series B round totaling EUR 65 million. The financing was co-led by Athos Service GmbH – the Strüngmann family office – and MIG ...
cancer
cancer immunotherapies
cancer therapeutics
+1